Home / Health / Miracle Drug Gleevec: A Second Chance at Life for Many
Miracle Drug Gleevec: A Second Chance at Life for Many
10 May
Summary
- Gleevec revolutionized cancer treatment, ushering in the era of targeted therapies.
- The drug offered a life-changing treatment for chronic myeloid leukemia.
- Initially expensive, Gleevec is now generic and affordable for patients.
In 1995, Mel Mann was diagnosed with a life-threatening blood cancer, chronic myeloid leukemia, and given only three years to live. His participation in clinical trials led him to Gleevec, an experimental drug that became a cornerstone of targeted cancer therapy. This breakthrough treatment, developed through the vision of Dr. Brian Druker and the work of scientists like Nicholas Lydon and biostatistician Insa Gathmann, targeted the specific genetic abnormality driving the cancer.
Gleevec received rapid FDA approval on May 10, 2001, marking a significant shift in oncology. Its success demonstrated the potential of targeting cancer at a molecular level, inspiring the development of over 100 subsequent targeted cancer drugs. While initially priced at $26,000 annually, Gleevec's transition to a generic medication has dramatically improved affordability and accessibility.
Today, patients diagnosed with chronic myeloid leukemia have a strong prognosis for living normal lives, a testament to Gleevec's enduring impact. Mel Mann, who was given three years to live in 1995, is now 69 and has witnessed his daughter grow up. The 25th anniversary of Gleevec's approval serves as a profound reminder of scientific innovation and its power to grant second chances at life.
